Macquarie Group LTD Kodiak Sciences Inc. Transaction History

Macquarie Group LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$7.57 - $12.5 $2,581 - $4,262	-341 Reduced 59.3%	234 $4,000
Q1 2022 May 16, 2022	SELL	$7.09 - $89.45 $4,856 - $61,273	-685 Reduced 54.37%	575 $4,000
Q4 2021 Feb 11, 2022	SELL	$80.85 - $128.49 $98,798 - $157,014	-1,222 Reduced 49.23%	1,260 $107,000
Q3 2021 Nov 12, 2021	SELL	$81.97 - $106.94 $17,541 - $22,885	-214 Reduced 7.94%	2,482 $239,000
Q2 2021 Aug 13, 2021	BUY	$77.2 - $126.54 $9,727 - $15,944	126 Added 4.9%	2,696 $250,000
Q1 2021 May 14, 2021	BUY	$110.45 - $164.47 $50,033 - $74,504	453 Added 21.4%	2,570 $291,000
Q4 2020 Feb 16, 2021	BUY	$60.78 - $154.03 $60,354 - $152,951	993 Added 88.35%	2,117 $314,000
Q2 2020 Aug 11, 2020	BUY	$42.74 - $66.25 $48,039 - $74,465	1,124 New	1,124 $61,000

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $303M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.